Table 2.
Characteristics of the included patients
| Parameters | AF with ischemic stroke group (n = 132) | AF without ischemic stroke group (n = 254) | P |
|---|---|---|---|
| Age (y), (mean ± SD) | 73.5 ± 9.3 | 73.1 ± 8.8 | .266 |
| Female (%) | 37.9 | 35.0 | .450 |
| BMI (kg/m2), (mean ± SD) | 24.5 ± 1.7 | 24.3 ± 2.1 | .355 |
| LncRNA ANRIL levels, (mean ± SD) | 14.3 ± 2.3 | 11.9 ± 1.9 | <.001 |
| NIHSS at the occurrence of ischemic stroke, median (IQR) | 11 (7, 17) | — | — |
| Infarct volume (mL), (IQR) | 22 (13, 33) | — | — |
| Medication, (%) | |||
| Dabigatran | 22.0 | 25.2 | .142 |
| Rivaroxaban | 23.5 | 15.3 | |
| Warfarin | 54.5 | 59.5 | |
| mRS at 6 mo, no. (%) | |||
| 0‐2 | 43.2 | — | — |
| 3‐6 | 56.8 | — | — |
| Total recurrence number of ischemic stroke at 6 mo, no. (%) | 56.1 | — | — |
| Hypertension (%) | 37.1 | 42.1 | .342 |
| Diabetes mellitus (%) | 16.7 | 15.0 | .783 |
| Smoking history (%) | 65.2 | 46.9 | <.001 |
| Drinking history (%) | 69.7 | 70.1 | .463 |
| Family history of ischemic stroke (%) | 8.3 | 7.5 | .718 |
| TC (mg/dL), median (mean ± SD) | 160.0 ± 26.5 | 155.6 ± 20.8 | .165 |
| HDL‐C (mg/dL), median (mean ± SD) | 48.1 ± 7.5 | 50.4 ± 8.5 | .089 |
| LDL‐C (mg/dL), median (mean ± SD) | 101.1 ± 24.7 | 98.3 ± 17.8 | .155 |
| Lp (a) (mg/L), median (mean ± SD) | 172.7 ± 18.7 | 173.4 ± 20.7 | .890 |
| PCT (ng/mL), median (mean ± SD) | 0.5 ± 0.1 | 0.4 ± 0.1 | .231 |
| Fibrinogen (g/L), median (mean ± SD) | 2.5 ± 0.5 | 2.6 ± 0.7 | .436 |
| D‐dimer (mg/L), median (mean ± SD) | 1.1 ± 0.3 | 1.0 ± 0.2 | .769 |
| Hs‐CRP (mg/dL), median (mean ± SD) | 0.9 ± 0.2 | 0.5 ± 0.1 | .265 |
Data are percentage, (mean ± SD) or median (IQR).
Abbreviations: AF, atrial fibrillation; BMI, body mass index; HDL‐C, high‐density lipoprotein‐cholesterol; Hs‐CRP, high‐sensitivity C‐reactive protein; IQR, interquartile range; LDL‐C, low‐density lipoprotein‐cholesterol; Lp (a), lipoprotein (a); mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PCT, procalcitonin; TC, total cholesterol.